OX40/OX40 ligand and its role in precision immune oncology
Cancer and Metastasis Reviews · 2024-09 · 43 (3) · 1001-1013
DOI: 10.1007/s10555-024-10184-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer and Metastasis Reviews, online erschienen am 25.03.2024. Verfasst von Bicky Thapa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. bithapa@mcw.edu. Hauptthemen laut MEDLINE: OX40 Ligand, Neoplasms, Receptors, OX40, Immunotherapy. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors have changed the treatment landscape for various malignancies; however, their benefit is limited to a subset of patients. The immune machinery includes both mediators of suppression/immune evasion, such as PD-1, PD-L1, CTLA-4, and LAG-3, all of which can be inhibited by specific antibodies, and immune-stimulatory molecules, such as T-cell co-stimulatory receptors that belong to the tumor necrosis factor receptor superfamily (TNFRSF), including OX40 receptor (CD134; TNFRSF4), 4-1BB (CD137; TNFRSF9), and glucocorticoid-induced TNFR-related (GITR) protein (CD357; TNFRSF18). In particular, OX40 and its binding ligand OX40L (CD134L; TNFSF4; CD252) are critical for immunoregulation. When OX40 on activated T cells binds OX40L on antigen-presenting cells, T-cell activation and immune stimulation are initiated via enhanced T-cell survival, proliferation and cytotoxicity, memory T-cell formation, and abrogation of regulatory T cell (Treg) immunosuppressive functions. OX40 agonists are in clinical trials both as monotherapy and in combination with other immunotherapy agents, in particular specific checkpoint inhibitors, for cancer treatment. To date, however, only a minority of patients respond. Transcriptomic profiling reveals that OX40 and OX40L expression vary between and within tumor types, and that only ~ 17% of cancer patients have high OX40 and low OX40L, one of the expression patterns that might be theoretically amenable to OX40 agonist enhancement. Taken together, the data suggest that the OX40/OX40L machinery is a critical part of the immune stimulatory system and that understanding endogenous expression patterns of these molecules and co-existing checkpoints merits further investigation in the context of a precision immunotherapy strategy for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. bithapa@mcw.edu.
- Center for Personalized Cancer Therapy, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA.
- Hematology and Oncology, Dartmouth Cancer Center, Lebanon, NH, USA.
- Labcorp Oncology, Durham, NC, 27560, USA.
- OmniSeq Inc, Buffalo, NY, USA.
- MCW Cancer Center and Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Milwaukee, WI, USA.
Zitieren
APA
Thapa, B., Kato, S., Nishizaki, D., Miyashita, H., Lee, S., Nesline, M. K., Previs, R. A., Conroy, J. M., DePietro, P., Pabla, S., & Kurzrock, R. (2024). OX40/OX40 ligand and its role in precision immune oncology. Cancer and Metastasis Reviews, 43(3), 1001-1013. https://doi.org/10.1007/s10555-024-10184-9
Vancouver
Thapa B, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, et al. OX40/OX40 ligand and its role in precision immune oncology. Cancer and Metastasis Reviews. 2024;43(3):1001-1013. doi:10.1007/s10555-024-10184-9
BibTeX
@article{Thapa2024,
author = {Thapa, Bicky and Kato, Shumei and Nishizaki, Daisuke and Miyashita, Hirotaka and Lee, Suzanna and Nesline, Mary K and Previs, Rebecca A and Conroy, Jeffery M and DePietro, Paul and Pabla, Sarabjot and Kurzrock, Razelle},
title = {OX40/OX40 ligand and its role in precision immune oncology},
journal = {Cancer and Metastasis Reviews},
year = {2024},
volume = {43},
number = {3},
pages = {1001--1013},
doi = {10.1007/s10555-024-10184-9}
}
EUVIMED